Regulus Therapeutics

Regulus Announces New Publication Showing Potential Therapeutic Benefit of Targeting microRNA-21 in Fibrosis

February 16, 2012

-New study published in Science Translational Medicine demonstrates microRNA-21 contributes to fibrogenesis in the kidney -Regulus, in partnership with Sanofi, developing novel anti-fibrotic therapies targeting microRNAs B.N. Chau et al. “MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways” Sci Transl Med 15 February 2012: Vol. 4, Issue 121, p. 121ra18 Sci. Transl. Med. […]

Read the full article →

Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer

December 12, 2011

-Regulus, Accelerate Brain Cancer Cure (ABC2) and Samsung Medical Center to Advance microRNA Therapeutics for Glioblastoma – LA JOLLA, Calif., Dec. 12, 2011 /PRNewswire/ – Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the initiation of a new discovery effort in microRNA therapeutics for the treatment […]

Read the full article →

Regulus Therapeutics to Present New In Vivo Data for microRNA-21 in Kidney Fibrosis

November 8, 2011

-Regulus Scientists to Provide Update on Lead Therapeutic Program at American Society of Nephrology Meeting- LA JOLLA, Calif., Nov. 8, 2011 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced presentations on its preclinical programs for the treatment of fibrosis at the American Association […]

Read the full article →

New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism

October 20, 2011

New publication in Nature shows therapeutic silencing of microRNA-33a/b for atherosclerosis: Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides K.J. Rayner et al. Nature 478, 404–407 (20 October 2011) http://www.nature.com/nature/journal/v478/n7369/full/nature10486.html Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism […]

Read the full article →

Nature Article Implicates microRNAs in the Pathogenesis of Obesity and Type 2 Diabetes

June 9, 2011

- Work of scientists with Regulus, Alnylam and ETH Zurich shows microRNAs 103/107 are upregulated in mouse models of obesity; targeting with anti-miRs improves glucose homeostasis and insulin sensitivity – LA JOLLA, Calif., and CAMBRIDGE, Mass., June 8, 2011 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines […]

Read the full article →

Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis

June 6, 2011

Research Article Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis Katey J. Rayner, Frederick J. Sheedy, Christine C. Esau, Farah N. Hussain, Ryan E. Temel, Saj Parathath, Janine M. van Gils, Alistair J. Rayner, Aaron N. Chang, Yajaira Suarez, Carlos Fernandez-Hernando, Edward A. Fisher, Kathryn J. Moore J. Clin. Invest. […]

Read the full article →

Recent microRNA Press

September 3, 2010

Rosetta Genomics to Host Second Quarter 2010 Conference Call on Wednesday, September 8, 2010 REHOVOT, Israel & PHILADELPHIA, Sep 02, 2010 (BUSINESS WIRE) – Rosetta Genomics, Ltd. , a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that the Company will release financial results for the three and six months ended June […]

Read the full article →

A Busy Month in the Business of microRNA

June 30, 2010

BUSINESSWIRE – June 29th – Alnylam Obtains Approvals to Initiate Phase I Study with ALN-TTR01 in Patients with TTR-Mediated Amyloidosis (ATTR) June 29th – Mirna Therapeutics Publishes Data Demonstrating In Vivo Proof of Concept for miR-34a microRNA Replacement Therapy in Cancer June 28th – Reimbursement for Rosetta Genomics’ miRview™ mets Test Now Available in Israel […]

Read the full article →

microRNA Clinical News

March 29, 2010

Regulus Therapeutics and Collaborators Publish Pre-clinical In Vivo Efficacy Data on microRNA Therapeutics targeting microRNA-10b in Models of Breast Cancer Metastasis March 29, 2010 8:00 AM EDT – New Paper Published in Nature Biotechnology Reports Therapeutic Efficacy of Targeting miR-10b as a New Anti-Metastatic Agent – CARLSBAD, Calif.–(BUSINESS WIRE)– Regulus Therapeutics Inc. today announced the […]

Read the full article →

microRNA Deal Struck

February 25, 2010

Regulus Therapeutics and GlaxoSmithKline Establish New Collaboration to … MarketWatch (press release)‎ Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA … Market Report — In Play (GSK) MSN Money GlaxoSmithKline and Regulus Therapeutics establish new collaboration to develop and commercialize microRNA Therapeutics Targeting miR-122 […]

Read the full article →